Watkin Phoebe L. Yang
Watkin Phoebe L. Yang's purchase track record
Watkin Phoebe L. Yang has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/8/2026 | GEHC | $63K | +13.1% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
GEHC Secures CE Mark for MINItrace Magni Cyclotron. GE HealthCare (GEHC) has received CE approval for its MINItrace Magni cyclotron, expanding its PETtrace™ solid‑target platform to include copper‑64. The approval follows research showing its End‑tial Control software can reduce fresh gas flow in anesthesia settings. In addition, HeartBeam has joined a European consortium to develop at‑home ECG monitoring for early detection of acute coronary syndrome. These developments broaden GEHC’s product portfolio and support its investment narrative.
Transaction History
| DOCS | ▼ Sell | Open Market | 1,290 | $34K | 9/30/2026 | View on chart |
| DOCS | ▲ Buy | Grant | 8,084 | $0 | 8/27/2026 | View on chart |
| GEHC | ▲ Buy | Open Market | 1,000 | $63K | 5/8/2026 | View on chart |
| GEHC | ▲ Buy | Grant | 3,586 | $0 | 5/7/2026 | View on chart |
| DOCS | ▲ Buy | Grant | 3,221 | $0 | 8/28/2025 | View on chart |
| GEHC | ▲ Buy | Grant | 3,092 | $0 | 5/28/2025 | View on chart |
| DOCS | ▼ Sell | Open Market | 2,889 | $217K | 2/12/2025 | View on chart |
| DOCS | ▲ Buy | Grant | 6,360 | $0 | 8/29/2024 | View on chart |
| DOCS | ▼ Sell | Open Market | 1,011 | $26K | 8/5/2024 | View on chart |
| DOCS | ▼ Sell | Open Market | 1,940 | $55K | 7/29/2024 | View on chart |
| GEHC | ▲ Buy | Grant | 2,440 | $0 | 5/21/2024 | View on chart |
| DOCS | ▲ Buy | Grant | 5,544 | $0 | 7/26/2023 | View on chart |
| GEHC | ▲ Buy | Grant | 3,584 | $0 | 5/23/2023 | View on chart |
| DOCS | ▲ Buy | Grant | 8,665 | $0 | 8/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Doximity Stock Rises Amid AI Spending and Q2 Earnings Focus
Doximity shares have recently surged alongside other software stocks, driven by discussions around AI spending and Q2 earnings performance. The company is currently trading well below its 52-week high, with analysts debating whether the current price reflects fair value given recent market momentum. This movement highlights the stock's sensitivity to broader technology sector trends and AI-related narratives.
Doximity Stock Rises Amid AI Spending and Q2 Earnings Focus. Doximity shares have recently surged alongside other software stocks, driven by discussions around AI spending and Q2 earnings performance. The company is currently trading well below its 52-week high, with analysts debating whether the current price reflects fair value given recent market momentum. This movement highlights the stock's sensitivity to broader technology sector trends and AI-related narratives.